ICON PLC ICLR
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research
Chart by TradingView
6/9
Piotroski F — financial health
2.1
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $8.3B | $229.3M | — | $862.0M | $9.2B |
| 2024 | $8.2B | $739.1M | — | $1.1B | $9.4B |
| 2023 | $8.1B | $554.2M | — | $1.0B | $9.2B |
| 2022 | $7.7B | $505.3M | — | $421.2M | $8.5B |
| 2021 | $5.5B | $153.2M | — | $735.4M | $8.1B |
| 2020 | $2.8B | $332.3M | — | $527.1M | $1.9B |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.1 (grey)
- Working capital / assets 0.019
- Retained earnings / assets 0.13
- EBIT / assets 0.027
- Equity / liabilities 1.299
Source: SEC EDGAR filings · CIK 0001060955 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.